Sagimet Biosciences Inc.
NASDAQ:SGMTBiotechnology
+$0.09 today
- Market cap
- $711.15M
- Beta
- 3.44
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.34
Volume 0.93M
Average 1.49M
SGMT Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
Sagimet Biosciences Inc.NASDAQ: SGMT
Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026
Accumulated OCI falls 93.4% from a year ago
Accumulated OCI stood at $8K at the end of Q1 FY2026, down 93.4% from a year earlier and down 93.3% from the prior quarter.
Context
- Accumulated OCI amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Accumulated OCI increased in 2 of the last 3 fiscal years.
What to watch
Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -93.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- 120K USD
- Year-over-year change
- -47.8%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 120K | -47.8% |
| FY2024 | 2024-12-31 | 230K | +666.7% |
| FY2023 | 2023-12-31 | 30K | +135.7% |
| FY2022 | 2022-12-31 | (84K) | — |
| FY2021 | 2021-12-31 | 0 | — |
Accumulated OCI vs competitors
How SGMT compares with its peers on the latest reported figures
- SGMT's Mar 2026 Accumulated OCI of $8K is the 2nd highest of the 11 companies compared; the peer median is -$48.5K.
- Its year-over-year change of -93.4% is the 5th highest of 7, against a peer median of -56.1%.
- Accumulated OCI amounts to 0.0% of total assets for SGMT, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $246K | -43.7% | — | 0.1% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $8K | -93.4% | — | 0.0% |
| Mar 2026 | $2K | -66.7% | +35.7% | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
ZURAZura Bio Limited | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | -$97K | -182.2% | — | 0.0% | |
| Mar 2026 | -$133K | -1050.0% | — | 0.1% | |
| Mar 2026 | -$263K | -32.2% | — | 0.1% | |
| Mar 2026 | -$368K | -45.5% | — | 0.2% | |
| Mar 2026 | -$241.01M | — | — | 0.1% | |
| Peer median (excluding SGMT) | -$48.5K | -56.1% | +35.7% | 0.0% | |
Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Sagimet Biosciences Inc.
NASDAQ:SGMT
Intrinsic Alpha fair value
Locked
Current Price
$10.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.